Optiscan has been featured in Small Caps regarding its recent announcement regarding the successful completion of the beta phase of testing for its cloud-based telepathology platform developed in partnership with Prolucid Technologies.

The article highlights the potential impact of the platform in advancing digital pathology by enabling real-time collaboration on patient imaging sessions and allowing remote users to make immediate and informed decisions.

"The new platform leverages Optiscan’s confocal imaging technology to natively generate digital pathology data and empower remote pathologists and clinicians to collaborate in real-time during imaging sessions. It streamlines the telepathology workflow with secure device-to-cloud connectivity and a dedicated web portal so that remote pathologists can seamlessly join the imaging session on a computer terminal and communicate their observations directly with the clinician."

Read the full article here.